Calcium and Phosphorus Metabolism in Patients Who Have Chronic Kidney Disease

2005 ◽  
Vol 89 (3) ◽  
pp. 631-647 ◽  
Author(s):  
William G. Goodman
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Phosphorus Metabolism ◽  
Calcium And Phosphorus

scholarly journals Current and Emerging Drugs in the Treatment of Anemia in Patients with Chronic Kidney Disease

2020 ◽  
Vol 23 ◽  
pp. 278-288
Author(s):  
Hongzhen Zhong ◽  
Wenshan Lin ◽  
Tianbiao Zhou
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Hypoxia Inducible Factor ◽  
Phosphorus Metabolism ◽  
Common Complication ◽  
Public Attention ◽  
Common Causes ◽  
Incident Heart Failure ◽  
Calcium And Phosphorus ◽  
Erythropoietin Stimulating Agents

Anemia is a common complication of chronic kidney disease (CKD), and its prevalence has shown a tendency to increase in many countries. Anemia is associated with incident heart failure and increases mortality in CKD patients, garnering public attention. Here, we reviewed recent studies about CKD with anemia, and tried to summarize the risks and causes and new progress in the treatment of renal anemia. Among the risks and causes, calcium and phosphorus metabolism disorders should be pointed out along with common causes such as iron and erythropoietin deficiencies, hypoxia, inflammation and uremic toxins, and so on. The new anti-anemia treatments mainly include hematopoietic materials supplementation, erythropoietin-stimulating agents, calcium and phosphorus regulators and hypoxia-inducible factor prolyl hydroxylase inhibitors.

scholarly journals Compromised calcium and phosphorus metabolism in patients with diabetes mellitus and chronic kidney disease

2012 ◽  
Vol 15 (4) ◽  
pp. 74-80 ◽  
Author(s):  
Margarita Stanislavovna Biragova ◽  
Svetlana Alexandrovna Gracheva ◽  
Sergey Andreevich Martynov
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Mineral Metabolism ◽  
Hormone Secretion ◽  
Therapeutic Agents ◽  
Phosphorus Metabolism ◽  
Novel Approach ◽  
Patients With Diabetes ◽  
Per Se ◽  
Calcium And Phosphorus

Disturbance of bone and mineral metabolism (BMM) is one of manifestations of chronic kidney disease (CKD), but its significance goes beyond bone disorders per se. Current discourse is as broad as to include vascular calcification, anemia and arterial hypertension, - conditions increasing mortality in patients with CKD. In this regard the active search for and development of novel approach to correction of BMM is under way. Apart from capacity to normalize calcium and phosphorus metabolism, parathyroid hormone secretion and to reduce morphologic alterations of bone tissue, modern therapeutic agents feature cardio- and renoprotective capabilities, which make them a treatment of choice for compromised BMM in CKD.

Inferring Disease Mechanisms from Epidemiological Data in Chronic Kidney Disease: Calcium and Phosphorus Metabolism

2009 ◽  
Vol 112 (3) ◽  
pp. c137-c147 ◽  
Author(s):  
Ana Pires ◽  
Teresa Adragão ◽  
Maria João Pais ◽  
José Vinhas ◽  
Hugo Gil Ferreira
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Epidemiological Data ◽  
Phosphorus Metabolism ◽  
Disease Mechanisms ◽  
Calcium And Phosphorus

Calcium and Phosphorus Homeostasis in Dogs with Spontaneous Chronic Kidney Disease at Different Stages of Severity

2010 ◽  
Vol 24 (1) ◽  
pp. 73-79 ◽  
Author(s):  
O. Cortadellas ◽  
M.J. Fernández del Palacio ◽  
J. Talavera ◽  
A. Bayón
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Calcium And Phosphorus

scholarly journals Elevated Fibroblast Growth Factor 23 Concentration: Prediction of Mortality among Chronic Kidney Disease Patients

2015 ◽  
Vol 6 (1) ◽  
pp. 73-82 ◽  
Author(s):  
Shahanas Chathoth ◽  
Samir Al-Mueilo ◽  
Cyril Cyrus ◽  
Chittibabu Vatte ◽  
Awatif Al-Nafaie ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Growth Factor ◽  
Kidney Disease ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Control Group ◽  
Phosphorus Metabolism ◽  
Fibroblast Growth ◽  
Saudi Population ◽  
Fgf23 Level

Background: The osteocyte-derived hormone, fibroblast growth factor 23 (FGF23), regulates the phosphorus metabolism and suppresses 1,25-dihydroxyvitamin D production, thereby mitigating hyperphosphatemia in patients with renal disorders. An elevated FGF23 level is suggested to be an early biomarker of altered phosphorus metabolism in the initial stages of chronic kidney disease (CKD) and acts as a strong predictor of mortality in dialysis patients. In the Saudi population, there is no report on the FGF23 level in CKD patients to date. This study aims to estimate the plasma FGF23 levels in the Saudi population and to correlate it with its clinical manifestations in order to ascertain its role in the pathogenesis of CKD patients. Methods: The FGF23 level in the plasma samples was determined using ELISA in a diverse cohort of 89 cases with stage 3-5 CKD and 100 healthy subjects. The plasma FGF23 level was correlated with other biochemical parameters. Results: The results revealed that the FGF23 level was markedly elevated among CKD patients compared to the control group, and a significant inverse correlation was observed between the FGF23 level and glomerular filtration rate. FGF23 elevation was approximately 40-fold among stage 5 patients compared to the control, while the elevation of phosphate, parathyroid hormone (PTH) and alkaline phosphatase was 2-, 3- and 8-fold in this stage, respectively. Conclusion: Elevated FGF23 levels may have a strong correlation with the disease pathogenesis. In addition, FGF23 might be a future therapeutic target to intervene against the progression of CKD as well as to increase patient survivability.

Sign in / Sign up

Export Citation Format

Share Document